JMP Securities Forecasts Strong Price Appreciation for Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise (NASDAQ:AXON) had its price objective boosted by investment analysts at JMP Securities from $610.00 to $725.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ target price would indicate a potential upside of 6.54% from the company’s current price.

Several other research firms have also issued reports on AXON. The Goldman Sachs Group raised their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a report on Monday, January 27th. TD Cowen started coverage on shares of Axon Enterprise in a research note on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price for the company. Needham & Company LLC upped their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Robert W. Baird lifted their price objective on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Finally, Northland Securities upped their target price on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $542.15.

Axon Enterprise Trading Up 2.7 %

NASDAQ AXON opened at $680.52 on Tuesday. The firm has a market capitalization of $51.89 billion, a PE ratio of 175.85, a price-to-earnings-growth ratio of 6.54 and a beta of 1.05. The business’s 50-day moving average price is $621.94 and its two-hundred day moving average price is $490.00. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise has a 12 month low of $255.58 and a 12 month high of $698.67.

Insider Buying and Selling at Axon Enterprise

In other news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $606.15, for a total value of $12,123,000.00. Following the transaction, the president now owns 208,166 shares in the company, valued at $126,179,820.90. This trade represents a 8.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey C. Kunins sold 21,834 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $593.88, for a total value of $12,966,775.92. Following the sale, the insider now owns 154,394 shares of the company’s stock, valued at $91,691,508.72. This trade represents a 12.39 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,545 shares of company stock valued at $30,721,337. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Axon Enterprise by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after buying an additional 35,320 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after acquiring an additional 127,769 shares during the period. Champlain Investment Partners LLC lifted its holdings in Axon Enterprise by 13.9% during the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after acquiring an additional 83,265 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Axon Enterprise by 1.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock worth $224,281,000 after purchasing an additional 9,090 shares during the last quarter. Finally, Groupama Asset Managment bought a new position in Axon Enterprise in the 3rd quarter valued at $200,000. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.